Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

10.86 UNCHANGED
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
The Best Russell 2000 Stocks to Buy Before they Rebound
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices. 
Via InvestorPlace
Arrowhead Pharmaceuticals's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of... 
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Arrowhead Pharmaceuticals Q1 Earnings
  Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Earnings Scheduled For February 2, 2022
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is likely to report quarterly earnings at $1.57 per share on revenue of $24.59 billion. 
Via Benzinga
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
Exposures COVID-19 Product Safety
GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market... 
Via Benzinga
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer. 
Via The Motley Fool
Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript
ARWR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy. 
Via Investor's Business Daily
Earnings Scheduled For November 22, 2021
Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya... 
Via Benzinga
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
Exposures Product Safety
Earnings Outlook For Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
Arrowhead Announces JNJ-75220795 in Development for NASH
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.